X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EB-101 (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets, is being developed for the treatment of recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder caused by a defect in the COL7A1 gene.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
The proceeds will support the Abeona’s ongoing preparations for launch and commercialization of EB-101 (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of recessive dystrophic epidermolysis bullosa.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Avenue Venture Opportunities Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 08, 2024
Details:
EB-101 (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets, is being developed for the treatment of recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder caused by a defect in the COL7A1 gene.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa, clinical efficacy and safety data appear adequate to support a BLA submission.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa, clinical efficacy and safety data appear adequate to support a BLA submission.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
EB-101 is an autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder without an approved treatment, in which patients suffer with severe epidermal wounds that impact the length and quality of their lives.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Abeona will use the net proceeds primarily to fund the preparations for commercialization of its product candidate EB-101, an investigational autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Nantahala Capital Management
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 07, 2023
Details:
Abeona intends to use the net proceeds to fund preparations for commercialization of its product candidate EB-101, an autologous, gene-corrected cell therapy currently being investigated for the treatment of recessive dystrophic epidermolysis bullosa.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Nantahala Capital Management
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 03, 2023
Details:
EB-101 is an autologous, engineered cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer with severe epidermal wounds that impact the length and quality of their lives.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
ABO-504 is an investigational preclinical gene therapy product candidates to tackle rare ocular diseases. It is designed to efficiently reconstitute the full-length ABCA4 gene by implementing a dual AAV vector strategy using the Cre-LoxP recombinase system.
Lead Product(s): ABO-504
Therapeutic Area: Genetic Disease Product Name: ABO-504
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
